Holen Sie sich die Stockscreener-App
0.178
0.22%
-0.0004
Handel nachbörslich:
.18
0.002
+1.12%
Schlusskurs vom Vortag:
$0.1784
Offen:
$0.18
24-Stunden-Volumen:
10.85M
Relative Volume:
0.51
Marktkapitalisierung:
$87.01M
Einnahmen:
$55.54M
Nettoeinkommen (Verlust:
$-180.40M
KGV:
-0.226
EPS:
-0.7877
Netto-Cashflow:
$-170.32M
1W Leistung:
+5.01%
1M Leistung:
+0.28%
6M Leistung:
-92.12%
1J Leistung:
-89.77%
1-Tages-Spanne:
$0.1729
$0.1816
1-Wochen-Bereich:
$0.16
$0.187
52-Wochen-Spanne:
$0.1138
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.178 | 97.48M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
$Gossamer Bio (GOSS.US)$ call me crazy but atlease you calling... - Moomoo
GOSS Upgraded by Leerink Partners -- Rating Changed to Outperform - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target - marketscreener.com
Leerink upgrades Gossamer Bio stock rating on FDA feedback By Investing.com - Investing.com UK
Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²
Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - Moomoo
Leerink Partners Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Cuts Target Price to $1 - Moomoo
GOSS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver Quantitative
Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million - TradingView
Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom - TechStock²
GOSS: Key Regulatory and Corporate Developments Announced - GuruFocus
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Benzinga
GOSS, Gossamer Bio Updates on Seralutinib and Strategic Developm - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gossamer Bio shares jump after FDA update and seralutinib rights return - Yahoo Finance
Gossamer Bio stock surges 25% on FDA regulatory update By Investing.com - Investing.com UK
Gossamer Bio stock surges 25% on FDA regulatory update - Investing.com
Why is Gossamer Bio stock surging today? By Investing.com - Investing.com Canada
Gossamer Bio plans September NDA submission for seralutinib By Investing.com - Investing.com Nigeria
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire
Gossamer Bio Inc (GOSS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gossamer Bio Inc (GOSS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
$Gossamer Bio (GOSS.US)$ mood today - Moomoo
Gossamer Bio Inc (GOSS) Balance Sheet - TradingKey
Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
$Gossamer Bio (GOSS.US)$ - Moomoo
GOSS|Gossamer Bio Inc|Price:0.147|Chg%:+0.011 - TradingKey
Gossamer Bio Inc (GOSS) Income Statement - TradingKey
Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gossamer Bio, Inc. Revenue Breakdown – NASDAQ:GOSS - TradingView
Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB - TradingView
GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006 - TradingKey
Form 13D/A Gossamer Bio For: 24 July By Investing.com - Investing.com Nigeria
Gossamer Bio Inc (GOSS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ETFs Investing in Gossamer Bio, Inc. Stocks - TradingView
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio stock edges higher as trial setbacks and restructuring reshape outlook - Ad-hoc-news.de
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio(GOSS) Stock Options Chain | Quotes & News - Moomoo
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Remains KeyPost-Announcement Reaction - dars.gov.et
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - AOL.com
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Price to earnings forward of Gossamer Bio, Inc. – MUN:4GB - TradingView
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio (GOSS) Income Statement & Earnings - Moomoo
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):